Pieris confirms in vivo activity of potent VEGF-specific Anticalin
PRS-050 targets VEGF, a key positive regulator of angiogenesis important in several diseases including cancer and neovascular eye disorders. According to the company, PRS-050 binds to all splice variants of VEGF-A with picomolar affinity and antagonizes VEGF binding to its receptors VEGF-R1 and VEGF-R2. PRS-050 shall inhibit in vitro VEGFinduced human endothelial cell proliferation with favorable potency compared to all currently approved VEGF antagonists. Complete inhibition of angiogenic and vascular permeability activities of VEGF by the Anticalin have now been demonstrated in appropriate in vivo models, according to Pieris.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.